Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

David S Lakomy; Diana L Urbauer; Shannon N Westin; Lilie L Lin

doi:10.1016/j.ctro.2019.12.005

Phase I study of the PARP inhibitor talazoparib with radiation therapy for locally recurrent gynecologic cancers

Clin Transl Radiat Oncol. 2019 Dec 28:21:56-61. doi: 10.1016/j.ctro.2019.12.005. eCollection 2020 Mar.

Authors

David S Lakomy^{1

2}, Diana L Urbauer³, Shannon N Westin⁴, Lilie L Lin²

Affiliations

¹ Dartmouth Geisel School of Medicine, Dartmouth College, Hanover, NH, United States.
² Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
⁴ Department of Gynecologic Oncology & Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Abstract

PARP inhibitors have been shown to radiosensitize tumor cells in both in vitro and in vivo studies. This is a phase I study that aims to determine the safety, tolerability, and maximally tolerated dose of talazoparib, a PARP inhibitor, when delivered concurrently with radiotherapy in women with recurrent gynecologic cancers.

Keywords: Dose escalation; Gynecologic cancer; PARP-inhibitors; Poly (ADP-ribose) polymerase; Radiosensitizer; Radiotherapy; Talazoparib.

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States